Objective: To determine the dose of remifentanil needed to achieve successful insertion of the Streamlined Liner of the Pharyngeal Airway (SLIPA) without the development of hypertension in 95% of the patients. Design: Randomised controlled trial. Setting: operating theatre of a university hospital. Methods: A total of 100 ASA I or II patients requiring SLIPA insertion were randomly assigned to receive normal saline (Group C) or one of the four different doses (0.5 g/kg [Group R0.5], 1.0 g/kg [Group R1], 1.5 g/kg [Group R1.5] or 2.0 g/kg [Group R2]) of remifentanil. Arterial blood pressure and heart rate were recorded at preanesthetic baseline, preinserton, and every one minute during the initial 3 minutes period after insertion. Results: A Probit model of remifentanil concentration was predictive of successful insertion of SLIPA without the development of hypertension. The ED95 of remifentanil needed to suppress haemodynamic response from SLIPA insertion was 1.39 g/kg (95% confidence interval, 1.06-2.61 g/kg). Conclusions: A single administration of remifentanil can effectively suppress haemodynamic changes due to the insertion of SLIPA. (Hong Kong j.emerg.med. 2013;23:210-217)
Introduction
Since the laryngeal mask airway (LMA) was first introduced by Brain in 1983, 1 the use of supraglottic airway devices (SGA), as a substitute for endotracheal intubation, has rapidly increased. Henceforth, many disposable SGAs have been created, including the Streamlined Liner of the Pharyngeal Airway (SLIPA, SLIPA Medical Ltd., London, UK), which is made of a plastic material molded in the appropriate anatomical shape. By closely fitting into the pharynx and palate, there is no need for additional cuff inflation to maintain a secure airway during positive pressure ventilation ( Figure 1 ). LMA unfortunately has a low sealing pressure. It can therefore cause inadequate ventilation and gastric distension during positive ventilation, and carries a risk of pulmonary aspiration in the event of regurgitation. 2 However, the SLIPA maintains a secure airway during positive pressure ventilation and a 50 ml empty internal space allows the removal of pharyngeal secretions, thus reducing the risk of pulmonary aspiration. 3 The SLIPA is also disposable, so it is safe and hygienic, 4 and comparatively cheap since there are no costs of cleaning and sterilisation associated with its use. 5 H o w e v e r, t h e r e a r e r e p o r t s o f s i g n i f i c a n t haemodynamic changes occurring when the SLIPA is inserted compared with the other SGAs. 6, 7 It is likely that the preformed shape of the SLIPA exerted more pressure on pharyngeal tissues, leading to larger haemodynamic changes. 4 Therefore, the administration of supplementary medication may be necessary to s u p p res s t his t y p e o f res p o n s e. A mo n g s u c h supplementar y medications, remifentanil that selectively applies to mu receptors has a rapid onset and offset, 8 can therefore effectively suppress haemodynamic changes resulting from the insertion of irritating SLIPA.
The best conditions for SGAs insertion with bolus of remifentanil have been reported, 9, 10 but the use of bolus remifentanil to suppress haemodynamic changes resulting from the insertion of SGAs has not been studied. The authors aimed to obtain an effective single dose that can be administered so that changes in blood pressure and heart rate, when inserting SLIPA, can be suppressed.
Subjects and methods
The study protocol was approved by the ethics committee at Chung-Ang University Hospital and written informed consent was obtained from all the participants before inclusion in the trial.
The subjects of this study consisted of adult patients, aged 20-65 years old, who were of American Society of Anesthesiologists physical status I or II, and were scheduled for surgery using general anaesthesia. Patients with cardiovascular or pulmonary disease, reflux oesophagitis, obesity (Body Mass Index >30 kg/m²), or were pregnant, or were addicted to opioids, sedatives, or other medications that can affect this study, were excluded. After obtaining approval from the Institutional Review Board, informed consent was then obtained from the patients after explaining the purpose and method of the study. The study was conducted in accordance to the Helsinki Declaration.
Patients were divided into five groups: the control group (Group C), remifentanil 0.5 g/kg group (Group R0.5), remifentanil 1 g/kg group (Group R1), remifentanil 1.5 g/kg group (Group R1.5), and remifentanil 2 g/kg group (Group R2). This was a randomised, double-blinded, placebo-controlled study. The randomisation into one of the five groups was The SLIPA is made of soft hollow plastic. Because the SLIPA resembles the anatomy of the pharynx, an inflatable cuff is unnecessary.
After insertion, an equal amount of fresh gas flow and a concentration of inhalation anaesthesia, as used when inducing anaesthesia, were applied to the mechanical respiration with a tidal volume of 8 ml/kg, according to the ideal body weight, respiration rate of 10 times/ min, and a ratio of inhalation and exhalation of 1:2.
No stimulation was applied, including a change of position. Before inducing anaesthesia, the systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate were measured twice in order to set the mean value as the baseline value (Pre-ind). The values were measured directly before insertion (Pre-int) and ever y minute after insertion for 3 minutes. Hypertension was defined to be systolic blood pressure increasing to more than 15% compared to the baseline value, and hypotension was when mean arterial pressure <60 mmHg or systolic blood pressure <80 mmHg. When the heart rate was higher than 100 per minute or lower than 50 beats per minute, tachycardia and bradycardia were determined to be present respectively. When either hypotension or bradycardia was observed in the groups, ephedrine (5 mg) or glycopyrrolate (0.2 mg) was IV injected accordingly.
The primary end point of this study was the systolic blood pressure 1 minute after insertion. In a pilot study of 10 subjects who had SLIPA inserted with an IV injection of normal saline, the standard deviation of systolic blood pressure was 8.9 mmHg. Hypothesizing that the standard deviation would be equal for the four groups using remifentanil, the results using the calculated value with an  error of 5% and a  error of 10% to distinguish the difference of systolic blood pressure 10 mmHg, showed that 20 subjects were required for each group of patients.
In continuous data, the Shapiro-Wilk test was used to verify the normal distribution of the collected data. When there was a normal distribution, Analysis of variance (ANOVA) was performed, Tukey was used as post-hoc, and the data was expressed as the mean  standard deviation. When the data did not have a normal distribution, Kruskal-Wallis was conducted, Bonferroni correction was used as post-hoc, and the data was expressed as the median value (interquartile based on random table generated using PASS 11 (NCSS, Kaysville, Utah, USA) with Wei's Urn model. The randomisation sequence was generated by a statistician who is not involved with the study. Patient group allocation was revealed to the investigator immediately prior to induction of anaesthesia by means of numbered, sealed envelopes.
The patients fasted from midnight, the day before surgery, and no premedication was given before anaesthesia. Upon arrival at the operating room, the patient was placed in a supine position, while noninvasive blood pressure (NIBP), ECG, a pulse oximeter, and end-tidal sevoflurane concentration were monitored. The patient was denitrogenated with 100% oxygen and thiopental sodium (5 mg/kg) was intravenous (IV) injected. After confirming that the patient became unconscious and blinking reflexes had disappeared, rocuronium (0.6 mg/kg) was administered simultaneously while performing manual ventilation with sevoflurane (2 vol%), N 2 O (1.5 L/min), and O 2 (1.5 L/min). Directly after administering rocuronium, the randomly selected experimental amount of medication was IV injected for 30 seconds. Sixty seconds after administering the experimental amount of study drugs, the SLIPA was inserted. The size o f t h e S L I PA w a s s ele c t ed a c c o rd in g t o t h e recommendation by the producer, which depended on sex and height: females 155 cm or shorter were given number 47, 155-165 cm number 49, 165 or taller number 51, whereas males 165 cm or shorter were given number 51, 165-175 cm number 53, 175 cm or taller number 55. The insertion was performed by a single anaesthesiologist with two years of experience in inserting LMA, and who also had experience in inserting the SLIPA more than 30 times before this experiment. When an insertion was attempted more than two times or took longer than one minute, the cases were excluded from the study. The time it took for the insertion (time taken from the removal of the face mask and the insertion to the first inflation of the chest) was measured. The anaesthesiologist, who inserted the SLIPA, subjectively evaluated the difficulty of the insertion (easy, normal, difficult), and the instrument was examined for traces of blood after removal. range). In the case of discontinuous data, the chisquared analysis or Fischer's exact test was performed. Within group, a comparison with the baseline value used the one-way repeatedly measured ANOVA, and Probit analysis was used to analyse the concentration of the remifentanil that suppressed hypertension. It was considered to be statistically significant when the p value was 0.05 or less. SPSS 18.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
Results
When an insertion of SLPIA was attempted, one patient in the group C, one in the group R1.5 and one in the group R2.0 took longer than one minute. Two patients in the group R0.5, two in the group R1.0 and one in the group R2.0 were attempted more than two times. Subsequently, eight patients fitting our inclusion criteria replaced the excluded patients. If exclusion occurred, the subsequent patient was allocated to the same group as the excluded patients by the investigator who was aware of the group assignment ( Figure 2 ).
There were no differences between the groups regarding age, sex, height, and weight of the patients (Table 1) . There were also no significant differences between the groups in time taken for insertion, difficulty, and trace of blood on the instrument (Table 2 ). A Probit model of remifentanil concentration was predictive of successful insertion of SLIPA without the development of hypertension (p for goodness-of-fit=0.830). The dose of remifentanil needed to achieve successful insertion of the SLIPA without the development of hypertension in 95% of the patients was 1.39 g/kg (95% confidence interval [CI], 1.06-2.61 g/kg). For 50%, the required dose of remifentanil was 0.51 g/kg (95% CI, 0.30-0.65 g/kg) ( Figure 3 ).
With regard to the changes in systolic blood pressure, diastolic blood pressure and mean arterial pressure, Group C had a significant increase when compared to the baseline value 1 and 2 minutes after the insertion. Group R0.5 showed a significant increase when compared to the baseline value 1 minute after the insertion. Group R1, Group R1.5, and Group R2 all showed a significant decrease when compared to the baseline value 1, 2, and 3 minutes after the insertion (Figures 4A-C) . With regard to the changes in heart rate, Group C, Group R0.5, and Group R1 all significantly increased until 3 minutes after the insertion and Group R1.5 significantly increased until 2 minutes after the insertion. There was no significant increase in Group R2 ( Figure 4D ). The incidence of hypertension and hypotension between the groups are shown in Table 2 . The incidence of hypertension was significantly lower in the other groups compared with Group C, and the incidence was significantly lower in Group R1.5 and Group R2 compared with Group R0.5. Cases of intravenous (IV) injection of ephedrine due to hypotension were found in three cases for Group R1.5 and five cases for Group R2. There were no complications such as chest stiffness in any of the groups.
Discussion
According to the results of our study, the insertion of SLIPA without remifentanil (Group C) causes haemodynamic changes, so the complications such as myocardial ischaemia, left heart failure, and cerebral haemorrhage can occur. However, there have not been any reports of the use of analgesics to suppress such outcomes, we therefore studied to find effective dose of remifentanil to attenuate haemodynamic responses. When anaesthesia was induced with 2 vol % sevoflurane, along with intravenous anaesthesia, a 95% effective dose (ED95) of remifentanil that can effectively suppress hypertension was 1.39 g/kg (95% CI 1.06-2.61 g/kg).
In existing research regarding single intravenous injection of remifentanil in endotracheal intubation, Th omp s on et a l 11 s u g ges t ed t h at 1 g /k g o f remifentanil be administered as a single administration, followed by continuous intravenous injections at 0.5 g/kg/min to suppress the haemodynamic changes. McAtamney et al 12 reported that 1.0 g/kg can reduce the pressor response of endotracheal intubation, but it cannot completely block the response, so further research on larger dose is necessary. Afterwards, Barclay reported that for completely blocking h a e mo d y n a mic c h a n g es d u r in g en d o t r a c h ea l intubation, remifentanil at 1.0 g/kg is ineffective, but remifentanil at 2.0 g/kg is able to produce the desired effect. When compared to the results of their study, the ED95 of 1.39 g/kg in our study was a smaller dose than what is required in endotracheal intubation.
The reason that this study conducted its research with a single IV injection, rather than continuous injection, was because the time needed for the insertion of the instrument after remifentanil administration was less than 1 minute, and the haemodynamic changes due to insertion only continue for 2-3 minutes.
One of the limitations of our study is that it was conducted in adults from the ages of 20 to 65. In elderly patients or patients with cardiovascular diseases, the physiological reserve is reduced, and changes in the autonomic nervous system arise so these patients experience a more rapid and unpredictable haemodynamic change during induction of anaesthesia. 19 Thus, there are limits in applying the results of this study. Secondly, the purpose of this study focused on the bolus dose of remifentanil to prevent the development of h y p er t e n s io n , t h e re f o re b lo o d p re s s u r e ma y decrease at the ED95. However, the ephedrine was intravenously injected when hypotension; Moreover the effect of remifentanil does not last long due to a rapid offset. Therefore continuous hypotension did not occur.
Conclusions
A single administration of remifentanil can effectively suppress haemodynamic changes due to the insertion of SLIPA without the need for concern about complications such as chest stiffness occurring.
Remifentanil has a fast acting of 1-2 minutes and a terminal elimination half-life of 10 minutes, 8 so when the administration dose and timing are adequately selected, a single administration can be effective.
After administering rocuronium, remifentanil was intravenously injected for 30 seconds, and the SLIPA was inserted after 60 seconds. There is no known research on the inserting condition of SGA when inducing anaesthesia with thiopental and rocuronium, but in endotracheal intubation, it has been reported with a satisfactory rate of 50% in 57 seconds, and 90% in 101 seconds, 14 so this was applied to our study. Also, remifentanil needs about 90 seconds to pass through the blood-brain barrier in order to achieve maximum effect, 15 so the above time was thought to be adequate for both drugs to have a maximum effect. Opioids can cause complications such as bradycardia, hypotension, and chest stiffness when inducing anaesthesia, so remifentanil was slowly injected for 30 seconds.
In th e results , all gro ups, exc luding R2 , had significantly increased heart rates when compared to the baseline value until 2 minutes. These results may be observed because the thiopental used in this study expanded the peripheral blood vessels and stimulated the sympathetic nervous system of baroreceptors due to reduced cardiac output. Rocuronium binds to acetylcholine receptors at site other than the neuromuscular junction and is therefore likely to produce other anticholinergic effects. An indirect, relaxation-induced reduction in preload caused by abdominal pooling may also contribute to the anticholinergic effects. 16 Opioids interact with the central nucleus of vagus nerves to cause bradycardia, while also suppressing the vasomotor centre of the medulla which relax the peripheral blood vessels. Thus, opioids are known to suppress haemodynamic changes in proportion to dose, 17 and as in the results of our study, it could be confirmed that the increase in heart rate faded as the dose of remifentanil increased. In the research of McAtamney et al, 18 regarding endotracheal intubation, after inducing anaesthesia with thiopental and rocuronium, as in our study, the heart rate of all groups using remifentanil 0.25 g/kg, 0.5 g/kg, and 1.0 g/kg significantly increased to 3 minutes.
